You might also like
Alterity Therapeutics Limited (ATHE) is a biotechnology company specializing in the development of therapeutic drugs for neurodegenerative diseases, with a primary focus on Parkinsonian disorders and related movement disorders. The company is a development-stage enterprise, advancing its pharmaceutical products through early to mid-stage clinical trials. Alterity does not sell commercial products but generates revenue through government grants, licensing, research collaborations, and interest income.
- Research and Development in Neurodegenerative Diseases - Focuses on discovering and developing therapeutic drugs targeting Parkinsonian disorders, including Multiple System Atrophy (MSA), a rare and debilitating condition with no approved treatments.
- ATH434 - Lead drug candidate in Phase 2 clinical trials for MSA, designed to address the underlying pathology of the disease.
- PBT2 - Previously developed for Alzheimer’s and Huntington diseases, with completed Phase 1 and Phase 2 trials.
- Discovery Platform - Maintains a chemical library of over 1,000 validated compounds designed for oral bioavailability and blood-brain barrier penetration, targeting the interrelationship of metals and proteins in neurodegenerative diseases.
- Collaborative Research - Partners with leading scientists and institutions, conducting research at The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute.
Name | Position | External Roles | Short Bio | |
---|---|---|---|---|
Dr. David Stamler Executive | Chief Executive Officer | None | Dr. Stamler has extensive experience in drug development, previously serving as CMO at Alterity and leading the development of ATH434 for neurodegenerative diseases. | View Report → |
Mr. Phillip Hains Executive | Chief Financial Officer and Company Secretary | Operates within Acclime Australia (formerly The CFO Solution) | Mr. Hains has over 30 years of experience in financial reporting and compliance, specializing in supporting public companies. | |
Mr. Brian Meltzer Board | Director | Director of Australia-Israel Chamber of Commerce; Chairman of Independence Australia | Mr. Meltzer has a background in investment banking and corporate advisory, with expertise in property transactions, venture capital, and syndications. | |
Mr. Geoffrey Kempler Board | Chairman of the Board | Chair of Hexima Ltd; Member of Turner Institute Advisory Board at Monash University | Founder of Alterity, Mr. Kempler has a background in psychology and investment, with significant contributions to the company's strategic direction. | |
Mr. Lawrence Gozlan Board | Director | Chief Investment Officer at Scientia Capital; Director of Opthea Limited | Mr. Gozlan is a life sciences investment specialist, leading Scientia Capital and holding directorships in several biotech companies. | |
Mr. Peter Marks Board | Director | Chairman of Newburyport Partners; Director of Noxopharm Limited, Iris Metals Limited, and Evergreen Lithium Limited | Mr. Marks has over 35 years of experience in corporate advisory and investment banking, focusing on life sciences and high-tech sectors. |